Effects of the Antifungal Antibiotic Clotrimazole on Human Cardiac Repolarization Potassium Currents

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2005 Dec 13

PMID 16341233

Citations 11

Authors

Miao Tian

Ming-Qing Dong

Shui-Wha Chiu

Chu-Pak Lau

Gui-Rong Li

Affiliations

Soon will be listed here.

Abstract

The antifungal antibiotic clotrimazole (CLT) shows therapeutic effects on cancer, sickle cell disease, malaria, etc. by inhibiting membrane intermediate-conductance Ca2+ -activated K+ channels (IKCa). However, it is unclear whether this drug would affect human cardiac K+ currents. The present study was therefore designed to investigate the effects of CLT on transient outward K+ current (Ito1), and ultra-rapid delayed rectifier K+ current (IKur) in isolated human atrial myocytes, and cloned hERG channel current (IhERG) and recombinant human cardiac KCNQ1/KCNE1 channel current (IKs) expressed in HEK 293 cells. It was found that CLT inhibited Ito1 with an IC50 of 29.5 microM, accelerated Ito1 inactivation, and decreased recovery of Ito1 from inactivation. In addition, CLT inhibited human atrial I(Kur) in a concentration-dependent manner (IC50 = 7.6 microM). CLT substantially suppressed IhERG (IC50 = 3.6 microM), and negatively shifted the activation conductance of IhERG. Moreover, CLT inhibited IKs (IC50 = 15.1 microM), and positively shifted the activation conductance of the current. These results indicate that the antifungal antibiotic CLT substantially inhibits human cardiac repolarization K+ currents including Ito1, IKur, IhERG, and IKs. However, caution is recommended when correlating the observed in vitro effects on cardiac ion currents to the clinical relevance.

Citing Articles

Cardiolipotoxicity, Inflammation, and Arrhythmias: Role for Interleukin-6 Molecular Mechanisms.

Ali A, Boutjdir M, Aromolaran A Front Physiol. 2019; 9:1866.

PMID: 30666212 PMC: 6330352. DOI: 10.3389/fphys.2018.01866.

A modified method for isolation of human cardiomyocytes to model cardiac diseases.

Guo G, Chen L, Rao M, Chen K, Song J, Hu S J Transl Med. 2018; 16(1):288.

PMID: 30348184 PMC: 6198433. DOI: 10.1186/s12967-018-1649-6.

Cardiac Potassium Channels: Physiological Insights for Targeted Therapy.

Jeevaratnam K, Chadda K, Huang C, Camm A J Cardiovasc Pharmacol Ther. 2017; 23(2):119-129.

PMID: 28946759 PMC: 5808825. DOI: 10.1177/1074248417729880.

Cardiac Ion Channel Regulation in Obesity and the Metabolic Syndrome: Relevance to Long QT Syndrome and Atrial Fibrillation.

Aromolaran A, Boutjdir M Front Physiol. 2017; 8:431.

PMID: 28680407 PMC: 5479057. DOI: 10.3389/fphys.2017.00431.

KCa3.1/IK1 Channel Regulation by cGMP-Dependent Protein Kinase (PKG) via Reactive Oxygen Species and CaMKII in Microglia: An Immune Modulating Feedback System?.

Ferreira R, Wong R, Schlichter L Front Immunol. 2015; 6:153.

PMID: 25904916 PMC: 4389654. DOI: 10.3389/fimmu.2015.00153.

References

Wassmann S, Nickenig G, Bohm M . Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med. 1999; 131(10):797. DOI: 10.7326/0003-4819-131-10-199911160-00034. View

Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff H, Makielski J . Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005; 144(6):840-8. PMC: 1576066. DOI: 10.1038/sj.bjp.0706095. View

Wulff H, Miller M, Hansel W, Grissmer S, Cahalan M, Chandy K . Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000; 97(14):8151-6. PMC: 16685. DOI: 10.1073/pnas.97.14.8151. View

Smith M, Zhang W, Naziruddin B, Cooper J, Patterson G, Mohanakumar T . Clotrimazole inhibits lung fibroblast proliferation in vitro: implications for use in the prevention and treatment of obliterative bronchiolitis after lung transplantation. Transplantation. 2000; 70(8):1263-7. DOI: 10.1097/00007890-200010270-00027. View

Raicu M, Florea S, Costache G, Popov D, Simionescu M . Clotrimazole inhibits smooth muscle cell proliferation and has a vasodilator effect on resistance arteries. Fundam Clin Pharmacol. 2000; 14(5):477-85. DOI: 10.1111/j.1472-8206.2000.tb00430.x. View

Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z . Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Mol Pharmacol. 2001; 59(5):1069-76. DOI: 10.1124/mol.59.5.1069. View

Macianskiene R, Sipido K, Flameng W, Mubagwa K . Suppression of transient outward potassium currents in mouse ventricular myocytes by imidazole antimycotics and by glybenclamide. J Pharmacol Exp Ther. 2001; 298(2):598-606. View

Iftinca M, Waldron G, Triggle C, Cole W . State-dependent block of rabbit vascular smooth muscle delayed rectifier and Kv1.5 channels by inhibitors of cytochrome P450-dependent enzymes. J Pharmacol Exp Ther. 2001; 298(2):718-28. View

Jensen B, Hertz M, Christophersen P, Madsen L . The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression. Expert Opin Ther Targets. 2002; 6(6):623-36. DOI: 10.1517/14728222.6.6.623. View

10.

Redfern W, Carlsson L, Davis A, Lynch W, Mackenzie I, Palethorpe S . Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003; 58(1):32-45. DOI: 10.1016/s0008-6363(02)00846-5. View

11.

Kohler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A . Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003; 108(9):1119-25. DOI: 10.1161/01.CIR.0000086464.04719.DD. View

12.

Brugnara C . Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol. 2003; 25(12):927-33. DOI: 10.1097/00043426-200312000-00004. View

13.

Gao Z, Lau C, Chiu S, Li G . Inhibition of ultra-rapid delayed rectifier K+ current by verapamil in human atrial myocytes. J Mol Cell Cardiol. 2004; 36(2):257-63. DOI: 10.1016/j.yjmcc.2003.11.003. View

14.

Roden D . Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350(10):1013-22. DOI: 10.1056/NEJMra032426. View

15.

Du X, Gao Z, Lau C, Chiu S, Tse H, Baumgarten C . Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases. J Gen Physiol. 2004; 123(4):427-39. PMC: 2217456. DOI: 10.1085/jgp.200409013. View

16.

Weuta H . Clinical studies with oral clotrimazole. Postgrad Med J. 1974; 50 Suppl 1:45-48. View

17.

Yoshida Y, Aoyama Y . Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol. 1987; 36(2):229-35. DOI: 10.1016/0006-2952(87)90694-0. View

18.

Rodrigues A, GIBSON G, Ioannides C, Parke D . Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins. Biochem Pharmacol. 1987; 36(24):4277-81. DOI: 10.1016/0006-2952(87)90670-8. View

19.

Alvarez J, Montero M, Garcia-Sancho J . High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992; 267(17):11789-93. View

20.

Rifai N, Sakamoto M, Law T, Platt O, Mikati M, Armsby C . HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. Clin Chem. 1995; 41(3):387-91. View